Drug
Precemtabart Tocentecan
Precemtabart Tocentecan: highest development phase Phase 3, developed by Merck KGaA. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Merck KGaA
Trials
| Drug | Phase | Indication |
|---|---|---|
| Precemtabart tocentecan NCT07549412 | Phase 3 | Metastatic Colorectal Cancer |
Latest
No recent events.
Follow Precemtabart Tocentecan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.